Indian stocks: Visit www.stage2stocks.com →

60 Degrees Pharmaceuticals, Inc.

Stage 4 · Declining · week 47

As of Oct 22, 2026, 60 Degrees Pharmaceuticals is in Stage 4, the downtrend phase, now in week 47 (since Nov 17, 2025). It closed at $0.88, 85.2% below its 52-week high and below its 200-day average, which is falling.

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. More about the company

$0.88
-1.57% today
$3.1M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is SXTP early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S? 36w
S4 20w
S4 13w
S4 15w
S4 49w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 36w → S4 6w → S1 7w → S4 20w → S1 7w → S4 13w → S1 8w → S4 15w → S1 4w → S4 49w current
Total tracked: 164 weeks across 10 stage runs.

SXTP among Biotechnology494th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…494SXTPStage 4 · wk 479−24.5%
vs 52W High
-85.2%
$0.83 lo$5.92 hi
85.2% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 47
1w13w26w
Week 47, extended decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-51.6%
200 DMA: $1.81 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.14x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-24.5%
3M
-40.8%
6M
-48.8%
YTD
-57.6%
1Y
-85.0%
Scan Membership
Not in any current scan.
Recent Stage Timeline
2026-10-22S4
Wk 47 · Vol 0.14x
2026-10-21S4
Wk 47 · Vol 0.19x
2026-10-20S4
Wk 47 · Vol 0.26x
2026-10-19S4
Wk 47 · Vol 0.31x
2026-10-16S4
Wk 46 · Vol 0.08x
2026-10-15S4
Wk 46 · Vol 0.28x
2026-10-14S4
Wk 46 · Vol 0.40x
2026-10-13S4
Wk 46 · Vol 0.28x
2026-10-12S4
Wk 46 · Vol 0.28x
2026-10-09S4
Wk 45 · Vol 0.28x
2026-10-08S4
Wk 45 · Vol 0.60x
2026-10-07S4
Wk 45 · Vol 1.01x
Moving averages & range
50 DMA
$1.04
200 DMA
$1.81
52W High
$5.92
52W Low
$0.83
5D Low
$0.83
Resistance levels (recent highs)
20d High
$1.44
60d High
$1.44
120d High
$1.78
250d High
$5.92
Next resistance
+64.4%
to 20d High
ROE
-332.9%
Profit margin 0.0%
Dividend Yield
0.00%
P/B -0.3

60 Degrees Pharmaceuticals: quick answers

What stage is 60 Degrees Pharmaceuticals in?

As of Oct 22, 2026, 60 Degrees Pharmaceuticals (SXTP) is in Stage 4, the downtrend phase. It entered Stage 4 on Nov 17, 2025 and is in week 47. What the four stages mean

Is 60 Degrees Pharmaceuticals in an uptrend?

No. 60 Degrees Pharmaceuticals is in a Stage 4 downtrend. It trades 51.6% below its 200-day average, which is falling.

How far is 60 Degrees Pharmaceuticals from its 52-week high?

60 Degrees Pharmaceuticals closed at $0.88 on Oct 22, 2026, 85.2% below its 52-week high of $5.92. Its 52-week low is $0.83.

How has 60 Degrees Pharmaceuticals performed over the past year?

As of Oct 22, 2026, 60 Degrees Pharmaceuticals is down 85.0% over the past year and down 57.6% so far in 2026.

Which sector and industry is 60 Degrees Pharmaceuticals in?

60 Degrees Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.